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Muscle-derived nitric oxide (NO) mediates fundamental physiological actions on skeletal 
muscle 1-4 including glucose uptake into muscle cells 5.  Recently, we have shown that the 
altered glucose metabolism in skeletal muscle of patients with type 2 diabetes (T2D) is 
associated with changes in the metabolic profile of individual muscle fibres 6, but fibre-
type specific changes in NO synthase (NOS) expression in skeletal muscle of T2D 
patients remain to be elucidated.  Here we investigated fibre-type related NOS 
expression in vastus lateralis muscle of T2D patients compared with healthy individuals 
with normal glucose tolerance (NGT).  Cytophotometrical assay and Western blotting 
did not reveal any quantitative differences between NOS expression in muscles from 
NGT and T2D subjects.  Positive NOS immunoreactivity in vastus lateralis of T2D 
patients was found to be associated with fast-oxidative glycolytic (FOG) muscle 
phenotype.  This indicates that NOS expression in T2D patients correlates both with 
skeletal muscle fibre type distribution and the activity of oxidative and glycolytic 
enzymes.   
 
 
There is increasing interest in the role of nitric oxide (NO) in common metabolic disorders 
such as type 2 diabetes (T2D).  The underlying mechanisms by which theses complications 
arise and manifest remain poorly understood.  Investigators have demonstrated that some of 
the changes that occur as a result of the diabetic environment include reduced bioavailability 
of NO 7.  NO originates via the oxidative L-arginine pathway catalyzed by a NO-synthase 
(NOS) family constituted by three distinct NOS isoforms (EC. 1.14.13.39).  Neuronal and 
endothelial NOS (also designated NOS1 and NOS3) were identified in and cloned from 
neuronal and endothelial cells, respectively, whereas inducible NOS was isolated originally 
from activated macrophages and was therefore called macrophage NOS (also designated 
NOS2).  Muscle fibre-type specific NOS expression in healthy skeletal muscles is profoundly 
described 1, 8.  We have earlier reported that NOS immunoreactivity was found to be 
associated primarily with fast-oxidative glycolytic (FOG) muscle fibres 8, 9.  However, studies 
about fibre related NOS expression in skeletal muscles from T2D patients are missing.   
Aim of the present study was to investigate the NOS1-3 expression in the vastus 
lateralis muscles of T2D patients in comparison to healthy individuals with NGT and to show 
a relationship of NOS1-3 to defined fibre types.  The muscle fibres were typed according to 
three classification systems as slow and fast (physiological fibre types), as I, IIA, IIX (myosin 
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based ATPase fibre types) and as SO (slow oxidative), FOG (fast oxidative glycolytic) and 
FG (fast glycolytic; physiological-metabolic fibre types).   We measured NOS expression in 
defined muscle fibres in situ cytophotometrically and in the muscle homogenate by Western 
blotting.   
Anthropometric and metabolic characteristics of subjects are summarized in Table 1.  
Age, sex distribution and anthropometric parameters were not significantly different between 
the NGT and T2D groups.  In parallel with the altered parameters of glucose metabolism and 
insulin sensitivity, maximal aerobic capacity (VO2max) was significantly lower in the T2D 
group.  The analysis of vastus lateralis muscle biopsies revealed that all three NOS isoforms 
were co-localized in the same fibres as evidenced from examination of adjacent 
immunolabelled sections, illustrated in Fig. 1.  To classify the NOS-positive fibres, we 
examined serial sections of vastus lateralis muscle subjected to enzyme histochemical 
reactions for demonstration of ATPase, GPDH and SDH activities and immunolabelled with 
antibodies against fast myosin, NOS1 (on behalf of all NOS isoforms) (Fig. 2).  Western 
blotting (Fig. 3) confirmed the expression of all three NOS isoforms in vastus lateralis 
muscles of NGT and T2D patients.  13 fibres were identified and classified.  The NOS-
positive fibres were FOG fibres including IIA, IIAX and IIX fibres. After further subtyping of 
FOG fibres in FOGI (more glycolytic) and FOGII (more oxidative), IIA fibres correlated to 
FOGI and IIX and IIAX fibres correlated to FOGII.   
In this study, we found a co-expression of NOS 1-3 in the metabolic defined fibre 
subtypes of FOG.  This agrees with our earlier findings in skeletal muscles of healthy subjects 
8, patients with type 1 diabetes (T1D) 10 and patients with Duchenne muscular dystrophy 9, 11.  
The correlation of NOS expression to the myosin-based ATPase fibre types was not obvious 
due to their metabolic heterogeneity.  However, NOS1-3-positive fibres were clearly defined 
as FOG fibres.  We have previously demonstrated that fast fibres without or very low 
oxidative metabolism fast glycolytic (FG) fibres were NOS-negative 8.  This implies that NO 
as modulator of muscle functions is involved in oxidative metabolism in connection with fast 
force development, which only occurs in FOG fibres.  Therefore, we confirm here the distinct 
role of FOG fibres in muscle function already suggested in our earlier studies 12.   
Cytophotometrical assessment of NOS1-3 immunoreactivity showed no significant 
differences between T2D and NGT subjects (Fig. 4).  Our findings that the expression of all 
three NOS isoforms in skeletal muscles does not significantly differs between NGT and T2D 
individuals are in accordance with the report of Kashyap et al. 13, 14 who did not found any 
differences in NOS protein content in muscle homogenates of healthy and T2D individuals.  
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In contrast to T2D patients, we measured reduced expression of NOS 1-3 expression 
in skeletal muscle of T1D patients, compared to NGT subjects 10.  These alterations could be 
linked to the reduction of FOG fibres 10 and the lack of C-peptid 15.  In muscles of T2D 
patients, frequency of FOG fibres and C-peptid level were not significantly changed, in 
contrast to T1D 6, 15.  In both T1D and T2D, chronic hyperglycemia occurs, the insulin 
sensitivity is preserved in T1D and impaired in T2D.  This suggests that hyperglycemia and 
impaired insulin sensitivity do not effect the NOS expression in skeletal muscle fibres.   
Notably, the NO levels in quadriceps muscle of T2D patients were earlier reported to 
be significantly higher than in healthy controls16.  In this study, we show that the NOS 
expression in FOG fibres does not significantly differ between NGT and T2D individuals.  
This poses a question; why total NO plasma levels in T2D patients are nevertheless 
significantly lower compared with healthy controls 17.  The apparent inconsistency can be 
explained by an increased oxidative stress in diabetes 16, 18 resulting in withdrawing NO from 
its regular physiological course via the scavenging actions of superoxides.  Consequently, the 
NO bioavailability gets drastically reduced 19.  As a result, the cell is getting short of bioactive 
NO and responses with up-regulation of NOS and other enzymes engaged in detoxification of 
ROS 20.  This is in line with our earlier hypothesis that NO deficiency with consequent muscle 
cell degeneration in muscular dystrophies may result from NO scavenging by superoxides 
rather than from reduced NOS expression 11.  Our findings suggest that antioxidants and 
pharmacological activators of the L-arginine-NO-cGMP pathway may appear to be useful 
adjuvants in the treatment of T2D patients.  A better understanding of the NO generation in 
muscles of T2D patients may provide further insight into fundamental mechanisms 
underlying the development of a clinical phenotype in diabetes.  
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Figure legends  
 
Figure 1  Serial sections of vastus lateralis muscle of a T2D patient immunoreacted for 
NOS1, NOS2 and NOS3.  A similar labelling pattern related to different fibre types was 
observed for all three isoforms.  As an example, some fibres were identified in each section.  
For fibre typing see Fig. 2.   
  
Figure 2  Fibre typing in serial sections of vastus lateralis muscle of a T2D patient.  
Immunostaining with fast myosin heavy chain (FAST), NOS 1 and activity of ATPase after 
acid (ATPase 4.3) or alkaline (ATPase 10.4) preincubation, GPDH, and SDH.  The 
NOS1immunostaining was demonstrated on behalf of all NOS isoforms which were 
coexpressed in the same fibre (see Fig. 1).  As an example, 13 fibres were identified and typed 
in each serial section: fibres 10-13 are slow fibres (type I, SO), fibres1- 9 are fast fibres (type 
II).  Subtypes of fast fibres: 1- 3 = IIAX  = FOGII , 4 and 5 = IIX= FOGII, 6-9 = IIA = FOGI  
 
Figure 3  Representative Western blots of NOS 1-3 expression in vastus lateralis muscle from 
NGT and T2D groups.  
 
Figure 4  Cytophotometrical assessment of NOS 1-3 immunoreactivity in vastus lateralis 
muscle from the NGT and T2D groups.  
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Methods 
Subjects and muscle biopsies 
Muscle biopsies were obtained from 25 Caucasian men (n = 12) and women (n = 13) that 
have been divided into 15 subjects (8 male and 7 female) with normal glucose tolerance 
(NGT) and 10 patients (4 male and 6 female) with type 2 diabetes (T2D).  The diagnosis of 
NGT and T2D was based on oral glucose tolerance tests (OGTT) following the ADA-criteria 
21.   Patients with malignant diseases or any acute or chronic inflammatory disease as 
determined by a leucocyte count > 7000 Gpt/l, C-reactive protein (CrP) > 5.0 mg/dl, or 
clinical signs of infection were excluded from the study.  The study was approved by the 
ethics committee of the University of Leipzig.  All subjects gave written informed consent 
before taking part in the study.  Body mass index (BMI) was calculated as weight (in 
kilograms) divided by the square of height (in meters).  Waist and hip circumferences were 
measured and waist-to-hip ratio (WHR) was calculated.  Percentage body fat was measured by 
dual-energy X-ray absorptiometry (DEXA).  All subjects completed a graded bicycle-
ergometer test to volitional exhaustion and had maximal oxygen uptake measured with an 
automated open circuit gas analysis system at baseline.   The highest oxygen uptake/minute 
reached was defined as the maximal oxygen uptake (VO2max).  Participants were admitted 
into the study at 9 am after 14 hours of fasting.  They had been asked to avoid vigorous 
exercise for at least 3 days before the muscle biopsy.  After administration of local anesthesia, 
muscle biopsy specimens were obtained from the vastus lateralis muscle using a biopsy 
device (SOMATEX, Teltow, Germany).  Muscle samples were powdered with talcum and 
immediately frozen in liquid nitrogen.  The samples were diveded into two parts.  One of the 
pieces was used for Western blotting, the other was transferred into a cryostat 1800 (Reichert 
Jung, Vienna, Austria).  10 µm thick cross sections were cut which were used for enzyme 
histochemical and immunohistochemical analysis.  To avoid possible variations in section 
thickness and incubation conditions, samples of NGT and T2D were mounted together on a 
cryostat chuck.    
 
Enzyme histochemistry  
Activity of succinate dehydrogenase (SDH, E.C. 1.3.5.1) was measured according to Lojda 
and Gutmann 22.  In a modified way, the method of Lojda and Gutmann 22 was used to 
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demonstrate activity of mitochondrial glycerol-3-phosphate dehydrogenase (GPDH, E.C. 
1.1.99.5): the medium consisted of 0.1 M phosphate buffer, pH 7. 4,5 mM DL-3-
glycerophosphate (disodium salt), 0.01% menadione and 0.5 mg/ml nitroblue tertazolium 
chloride (NBT).  The incubation took 20 min at 37°C.  The myofibrillar adenosine 
triphosphatase (ATPase, E.C. 3.6.1.32) activity was demonstrated after acid and alkaline 
preincubations at pH 4.35, 4.55 and 10.4, respectively 23.  Each time, control reactions were 
done on serial sections by missing substrate.   
 
Myosin heavy chain (MHC) isoforms- Immunohistochemistry  
Mouse monoclonal antibodies against slow and fast MHC isoforms were used following the 
guidelines recommended by the manufacturers (Novocastra Laboratories Ltd, Newcastle, 
UK).  In brief, serial sections were incubated with the primary MABs 60 min at 37° C 
followed by incubation with rabbit-anti-mouse secondary AB (Jackson Immuno Research 
Laboratories, Inc, USA) for 60 min at 37°C and mouse PAP-complex (Jackson Immuno 
Research Laboratories, Inc, USA) 60 min at room temperature.  The visualization was 
performed by incubation with 3,3-diaminobenzidine.  After dehydration, the sections were 
mounted in Entellan (Merck, Darmstadt, Germany).  
 
Fiber typing  
Fibres were typed into slow and fast according to their slow or fast MHC-isoforms detected 
immunohistochemically as described above.  According to the different acid and alkali 
labilitiy of the ATPase activity of the MHC isoforms demonstrated with enzyme 
histochemistry, four fibre types I, IIA, IIAX, IIX were differentiated.  After acid 
preincubation at pH 4.25 and 4.55, respectively, type I fibres showed strong ATPase activity, 
IIAX fibres were weakly stained, IIX fibres were moderate and IIA fibres were not stained.  
IIAX fibres are hybrid fibres, their staining intensity was intermediate between that of IIA and 
IIX.  After alkaline preincubation, type I fibres showed weak, IIA, IIAX and IIX fibres strong 
ATPase reaction.  The physiological-metabolic fibre typing into SO (slow oxidative), FOG 
(fast oxidative glycolytic) and FG (fast glycolytic) has been described previously (Punkt 
2002), based on cytophotometrically quantified activities of SDH (marker of oxidative 
activity) and GPDH (marker of glycolytic activity) and the immunoreactivity against slow and 
fast myosin in serial cross sections of the same fibre.  SO fibres showed high SDH and low 
GPDH activity, FG fibres showed high GPDH and very low SDH activity.  FOG fibres were 
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subdivided into FOG I (moderate SDH and high GPDH activity) and FOG II (high SDH and 
moderate GPDH activity).   
 
Cytophotometry  
End-point measurements were performed with a computer-controlled microscope photometer 
MPM 200 with a scanning table (Carl Zeiss, Oberkochen, Germany).  The absorbance of the 
NOS-immunostained muscle fibres of NGT and T2D muscles arranged arranged in pairs on 
the same glass slide were measured.  Three sections per muscle biopsy were evaluated.  By 
mounting samples of NGT and T2D muscles on one and the same cryostat chuck the sections 
to compare were subjected the same cutting step and identical staining conditions.  
Differences in absorbance data between NGT and T2D muscle fibres reflect changes in NOS 
immunoreactivity in T2D muscles.   
 
NOS–Immunohistochemistry  
Cryostat sections were fixed in cold acetone for 15 min and thoroughly air dried for 30 min.  
After rinsing in PBS, nonspecific binding sites were blocked by incubation in PBS containing 
10% goat serum for 30 min.  PBS was used for all rinses and dilutions.  Cryostat sections 
were incubated overnight at 4°C with rabbit primary polyclonal Abs recognizing NOS 1, NOS 
2, NOS 3 (Transduction Laboratories, Lexington, KY).  Primary Ab was diluted to a final 
concentration of 1.0 μg/ml.  To quench endogeneous peroxidase activity, sections were 
treated with methanol containing 1.2% H2O2 for 15 min.  Bound primary Abs were detected 
by employing horse radish peroxidase-conjugated goat-anti-rabbit secondary Abs which was 
followed by tyramide signal amplification (TSA-kit, NEN, Cologne, Germany) and ABC 
technique using the Vectastain ABC-kit (Vector Laboratories, USA).  The visualization was 
performed using NovaRed substrate kit for peroxidase (Vector).  The reaction was observed 
under the microscope and was stopped by rinsing with water after 4-10 minutes.  Control 
incubations were: i) omission of primary Ab; and ii) substitution of primary Ab by rabbit IgG 
(Dianova, Hamburg, Germany) at the same final concentration as the primary Ab.  
 
NOS-Western blotting 
Total protein of skeletal muscle biopsies harvested in PBS and sedimented by centrifugation 
was homogenized in 10 mM Hepes (pH 7.5) containing 0.2 mM 
phenylmethylsulfonylfluoride (PMSF) and 0.1 mM dithiothreitol (DTT) using an Ultra Turrax 
(IK, Staufen, Germany) at 30.000 rpm for 3x5 sec.  The final pellet was suspended in 0.75 ml 
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10mM Hepes (pH 7.5), 250 mM sucrose, 0.2 mM PMSF and 0.1 mM DTT and was stored at 
–80°C until use.  40 µg protein samples solubilized in SDS sample buffer were separated by 
7.5% Laemmli-polyacrylamide gel electrophoresis.  The electro transfer of the separated 
proteins was performed onto polyvinylidenedifluoride membranes (Boehringer, Mannheim, 
Germany).  Primary anti-NOS antibodies were diluted according to the manufacturer’s 
instructions (Transduction Laboratories, Lexington, KY).  As positive controls for NOS 1-3 
cerebellum, macrophage and endothelial lysates (Transduction Laboratories, Inc.) were used.  
The secondary antibody was peroxidase-labeled anti-rabbit IgG (Sigma, St.  Louis MO, USA; 
dilution 1:15.000).  The visualisation of the immunoreaction was performed by using an ECL-
Kit (Amersham, Buckinghamshire, UK).  
 
Statistical analyses 
Data are shown as means ± SD.  The NGT and T2D groups were compared using the paired 
Student’s t test.  Statistical analysis was performed using SPSS version 12.0 (Chicago, IL).  P 
values < 0.05 were considered to be statistically significant.  
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Table 1  Anthropometric and metabolic parameters of the subjects   
Parameter NGT T2D 
n 
Sex (male/female) 
Age (years) 
BMI (kg/m2) 
Body fat content (%) 
Waist-to-hip ratio 
VO2max (ml kg-1min-1) 
Fasting plasma glucose (mmol/l) 
HbA1c (%) 
Fasting plasma insulin (pmol/l) 
Glucose infusion rate, clamp (ml/min) 
15 
8/7 
56.8±7.9 
31.4±3.2 
33.6±6.6 
1.24±0.12 
23.5±2.7 
5.34±0.4 
5.15±0.31 
91.9±42 
87.5±13 
10 
4/6 
58.7±6,4 
32.1±3.4 
35.1±8.1 
1.27±0.17 
17.4±3.8* 
6.55±0.9 * 
6.6±0.4* 
157± 51* 
29±12 * 
Data are means ± SD. * p < 0.05 for NGT vs. T2D subjects  
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